Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCB0942 add-on study in adults with highly drug-resistant focal epilepsy
NL-OMON44054Phase 2Active, not recruiting
- Sponsor
- UCB
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Focal Onset Epilepsy comparing UCB0942 then open-label UCB0942 with Placebo then open-label UCB0942 (2 arms). Primary endpoint: 75% responder rate. Started May 2016; status: active, not recruiting.
02
Drugs
padsevonil
03
Conditions
Focal Onset Epilepsy
Beyond the preview
Go deeper on NL-OMON44054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44054.